Sector News

Colorcon delivers a breakthrough with Nutrafinish Mineral-Free Coatings for fast growing nutritional supplements market

April 16, 2022
Life sciences

Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces a breakthrough with the launch of the latest mineral – free addition to the label friendly Nutrafinish® P Film Coatings for the nutritional and dietary supplements market.

Consumers continue to call for products with ingredient lists that are easy to understand and only contain materials they view as of “natural” origin. Manufacturers are looking to satisfy these consumer needs with sustainable ingredients that can achieve label friendly status while not compromising on product quality, manufacturing efficiency, or cost-in-use.
Colorcon leads the evolution in coating products for dietary supplements by bringing to the market mineralfree Nutrafinish, Label Friendly Coatings that satisfy consumer desires and meet manufacturer’s needs, without adversely affecting tablet appearance. The latest addition to the Nutrafinish, label friendly product line is formulated without the use of TiO2, talc and calcium carbonate to deliver a high level of opacity to cover unsightly or dark tablet cores.

Kelly Boyer, Vice President Film Coatings explains: “The launch of Colorcon’s new mineral-free formulations provides the nutritional market with alternative coating systems that combines superior opacity with excellent stability especially when using non-synthetic colorants. This product line expansion includes a new white formulation, which delivers superior opacity and the option to pigment using non-synthetic colors enables a broad choice of the color palette to provide aesthetics and brand differentiation”.

Dr. Ali Rajabi-Siahboomi adds: “Getting the right balance of components for this type of coatings is challenging without the use of opacity and whitening ingredients like TiO2 and calcium carbonate. Through Colorcon’s in-depth knowledge of materials and coating technology, these new formulations provide simple preparation and use, with the label friendly claims the industry and consumers are demanding; along with a perfectly finished tablet.”

Through its extensive portfolio of fully formulated coatings Colorcon provides scope for customers to reduce complexity and time-to-market by delivering high-quality products, with ingredients carefully selected from commonly used food ingredients or approved food additives that meet local regulatory requirements and support clean-label claims. This is all backed by Colorcon’s superior and dedicated technical support, along with regulatory expertise.

By Colorcon, Press Release

Source: colorcon.com

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”